evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
Published 8 months ago • 80 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
1:19
predicting the outcomes of patients with aml treated with cpx-351 based on eln risk stratification
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
1:30
the current role of cpx-351 in aml and clinical trials evaluating this agent
-
3:21
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
3:31
risk stratified analysis of cpx-351 versus 7 3 in older adults with aml
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
5:04
evaluating cpx-351 against 7 3 in older newly diagnosed aml
-
2:58
evolution of the aml treatment paradigm
-
0:36
the promise of cpx-351 in secondary aml
-
1:47
choosing between cpx-351 and flag-ida in newly diagnosed and r/r aml
-
2:21
cpx-351 for high-risk aml
-
1:40
the role of cpx-351 in the aml treatment landscape & insights into the amlsg 30-18 trial
-
1:10
time-lapse | embryo monitoring system
-
2:01
myeloid precursor proliferation and differentiation | protocol preview
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
0:53
an overview of optimal sequencing therapy in aml